Cytokinetics Names Nancy Wysenski to Board of Directors
November 20 2020 - 7:30AM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that
Nancy Wysenski has been appointed to the company’s Board of
Directors. Ms. Wysenski brings more than 25 years of experience in
the biopharmaceutical industry. Throughout her career, she has
focused on commercial launch strategy, executive leadership,
operational excellence and optimizing market access across many
therapeutic areas including the rare disease and specialty
pharmaceutical sectors.
“We are pleased to welcome Nancy to our Board,”
said Robert I. Blum, Cytokinetics’ President and Chief Executive
Officer. “As a seasoned commercial and organizational leader, her
track record of success in commercialization and corporate
governance will be invaluable as we advance our pipeline toward
marketing authorizations and navigate the evolving landscape of
access for patients with high unmet needs.”
Ms. Wysenski served as the Executive Vice
President and Chief Commercial Officer of Vertex Pharmaceuticals
from December 2009 through her retirement in June 2012. During her
tenure at Vertex, Ms. Wysenski was responsible for the launches of
Incivek and Kalydeco. Prior to joining Vertex, Incorporated, Ms.
Wysenski held the position of Chief Operating Officer of Endo
Pharmaceuticals, Inc., a specialty pharmaceutical company, where
she led sales, marketing, commercial operations, supply chain
management, human resources and various business development
initiatives. Prior to her role at Endo, Ms. Wysenski participated
in the establishment of EMD Pharmaceuticals, Inc., where she held
various leadership positions, including the role of President and
Chief Executive Officer from 2001 to 2006 and Vice President of
Commercial from 1999 to 2001. From 1984 to 1998, Ms. Wysenski held
several sales-focused roles at major pharmaceutical companies,
including Vice President of Field Sales for Astra Merck, Inc. Ms.
Wysenski serves as a member of the board of directors of Provention
Bio Inc., and Alkermes plc, each a publicly traded pharmaceutical
company. Ms. Wysenski formerly served as a director for Tetraphase
Pharmaceuticals, Dova Pharmaceuticals Inc., Reata Pharmaceuticals,
Inc. and Inovio Pharmaceuticals, Inc. She is a founder of the
Research Triangle Park chapter of the Healthcare Business Women's
Association and served on the Nominating Committee and National
Advisory Board of the Healthcare Businesswomen's Association.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and next-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating with Amgen Inc.
(Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle
activator. Omecamtiv mecarbil is the subject of an international
clinical trials program in patients with heart failure including
GALACTIC-HF, of which topline results were recently reported, and
METEORIC-HF, which is ongoing. Amgen holds an exclusive worldwide
license to develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization in Europe and
certain other countries. Cytokinetics is developing reldesemtiv, a
fast skeletal muscle troponin activator (FSTA) for the potential
treatment of ALS and other neuromuscular indications following
conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The
company is considering potential advancement of reldesemtiv to
Phase 3 pending ongoing regulatory interactions. Cytokinetics is
collaborating with Astellas Pharma Inc. (Astellas) to research,
develop and commercialize other novel mechanism skeletal sarcomere
activators (not including FSTAs). Licenses held by Amgen and
Astellas are subject to specified co-development and
co-commercialization rights of Cytokinetics. Cytokinetics is also
developing CK-274, a novel cardiac myosin inhibitor that company
scientists discovered independent of its collaborations, for the
potential treatment of hypertrophic cardiomyopathies. Cytokinetics
has granted Ji Xing Pharmaceuticals Limited an exclusive license to
develop and commercialize CK-274 in China and Taiwan, in accordance
with Cytokinetics’ planned global registration programs.
Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of
CK-274 in patients with obstructive HCM. Cytokinetics continues its
over 20-year history of pioneering innovation in muscle biology and
related pharmacology focused to diseases of muscle dysfunction and
conditions of muscle weakness.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements, and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics' and its partners'
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management's current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics' business outlined in Cytokinetics'
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics' actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press
release speak only as of the date of this press release.
Cytokinetics assumes no obligation to update its forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:CytokineticsDiane
WeiserSenior Vice President, Corporate Communications, Investor
Relations(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024